Nimotuzumab with Concurrent Chemoradiotherapy for High-Risk Locally Advanced Nasopharyngeal Carcinoma

This clinical trial focuses on high-risk nasopharyngeal carcinoma, a type of cancer that affects the nose and throat. Despite existing treatments like induction chemotherapy combined with concurrent chemoradiotherapy, around 20-30% of patients still experience recurrence and metastasis. The study aims to improve survival rates for these high-risk patients by exploring whether increasing treatment intensity during concurrent chemoradiotherapy can be beneficial. The trial involves the use of Nimotuzumab, a drug that blocks epidermal growth factor (EGFR), a known therapeutic target for nasopharyngeal carcinoma. During the trial, participants will undergo concurrent chemoradiotherapy with or without Nimotuzumab. The primary outcome being measured is progression-free survival (PFS), which is defined from the date of randomization to the date of first documentation of progression or death due to any cause. This study hopes to provide new evidence for individualized comprehensive treatment of locally advanced nasopharyngeal carcinoma.